StonvexLoading…
StonvexStonvexStonvexCore line items from TMHC's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.39B | $8.12B | $6.02B | $3.93B |
Operating Income | Not available | Not available | Not available | Not available |
Net Income | $98.63M | $782.50M | $608.48M | $407.04M |
EPS (Diluted) | $1.01 | $7.77 | $6.00 | $3.99 |
Total Assets | $9.77B | $9.84B | $9.63B | $9.45B |
Total Liabilities | $3.52B | $3.53B | $3.43B | $3.39B |
Cash & Equivalents | $652.93M | $850.04M | $370.59M | $130.17M |
Free Cash Flow OCF − CapEx | $-20.39M | $776.97M | $141.67M | $-64.92M |
Shares Outstanding | 97.53M | 96.54M | 101.38M | 102.02M |